- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/3 | 0.71 | 39.64 | 16.84 | 1.95 | 62.28 | 1.95 | N/A | 可吸收防沾黏凝膠及關節腔注射劑業務銷售增加。 | ||
| 2024/2 | 0.51 | -31.96 | 108.2 | 1.25 | 108.01 | 2.06 | N/A | 可吸收防沾黏凝膠及關節腔注射劑業務銷售增加 | ||
| 2024/1 | 0.74 | -8.5 | 107.89 | 0.74 | 107.89 | 2.17 | N/A | 可吸收防沾黏凝膠、關節腔注射劑及膀胱灌注液業務銷售增加。 | ||
| 2023/12 | 0.81 | 30.79 | 25.55 | 7.13 | 27.92 | 2.03 | 0.43 | - | ||
| 2023/11 | 0.62 | 3.37 | 40.47 | 6.32 | 28.23 | 1.79 | 0.49 | - | ||
| 2023/10 | 0.6 | 5.89 | 17.59 | 5.7 | 27.03 | 1.97 | 0.44 | - | ||
| 2023/9 | 0.57 | -29.58 | -16.15 | 5.1 | 28.24 | 2.06 | 0.46 | - | ||
| 2023/8 | 0.81 | 16.81 | 107.79 | 4.53 | 37.34 | 2.21 | 0.43 | 可吸收防沾黏凝膠、關節腔注射劑及皮下填補劑業務銷售增加。 | ||
| 2023/7 | 0.69 | -3.21 | 17.69 | 3.73 | 27.96 | 2.02 | 0.46 | - | ||
| 2023/6 | 0.71 | 14.72 | 25.73 | 3.04 | 30.55 | 1.83 | 0.52 | - | ||
| 2023/5 | 0.62 | 24.09 | 42.17 | 2.32 | 32.1 | 1.72 | 0.55 | - | ||
| 2023/4 | 0.5 | -17.18 | 56.58 | 1.7 | 28.78 | 1.35 | 0.71 | 可吸收防沾黏凝膠及關節腔注射劑業務銷售增加。 | ||
| 2023/3 | 0.6 | 148.82 | 5.97 | 1.2 | 19.93 | 1.2 | 0.81 | - | ||
| 2023/2 | 0.24 | -32.06 | 3.96 | 0.6 | 38.26 | 1.25 | 0.78 | - | ||
| 2023/1 | 0.36 | -44.74 | 78.21 | 0.36 | 78.21 | 1.45 | 0.67 | 皮下填補劑業務銷售增加。 | ||
| 2022/12 | 0.65 | 46.34 | -5.29 | 5.57 | 10.24 | 1.6 | 0.6 | - | ||
| 2022/11 | 0.44 | -13.46 | 16.81 | 4.93 | 12.67 | 1.63 | 0.59 | - | ||
| 2022/10 | 0.51 | -24.49 | 49.43 | 4.49 | 12.28 | 1.57 | 0.61 | - | ||
| 2022/9 | 0.68 | 74.52 | 64.52 | 3.97 | 8.8 | 1.65 | 0.59 | 關節腔注射劑及可吸收防沾黏凝膠業務銷售增加。 | ||
| 2022/8 | 0.39 | -33.83 | -29.74 | 3.3 | 1.74 | 1.54 | 0.64 | - | ||
| 2022/7 | 0.59 | 3.4 | 88.67 | 2.91 | 8.19 | 1.59 | 0.62 | 可吸收防沾黏凝膠、皮下填補劑及關節腔注射劑業務銷售增加。 | ||
| 2022/6 | 0.57 | 29.72 | 4.93 | 2.33 | -2.29 | 1.32 | 0.64 | - | ||
| 2022/5 | 0.44 | 36.66 | 2.89 | 1.76 | -4.41 | 1.33 | 0.64 | - | ||
| 2022/4 | 0.32 | -43.94 | 4.97 | 1.32 | -6.59 | 1.12 | 0.76 | - | ||
| 2022/3 | 0.57 | 144.1 | -1.2 | 1.0 | -9.76 | 1.0 | 0.81 | - | ||
| 2022/2 | 0.23 | 16.45 | 2.66 | 0.43 | -18.98 | 1.12 | 0.73 | - | ||
| 2022/1 | 0.2 | -70.63 | -34.96 | 0.2 | -34.96 | 1.26 | 0.64 | - | ||
| 2021/12 | 0.68 | 80.5 | 35.29 | 5.06 | 8.28 | 1.4 | 0.59 | - | ||
| 2021/11 | 0.38 | 10.7 | 24.02 | 4.37 | 5.0 | 1.13 | 0.73 | - | ||
| 2021/10 | 0.34 | -16.87 | -32.99 | 3.99 | 3.5 | 1.3 | 0.64 | - | ||
| 2021/9 | 0.41 | -25.47 | 72.3 | 3.65 | 9.06 | 1.27 | 0.53 | 關節腔注射劑及可吸收防沾黏業務銷售增加。 | ||
| 2021/8 | 0.55 | 77.67 | -21.44 | 3.24 | 4.21 | 1.4 | 0.49 | - | ||
| 2021/7 | 0.31 | -42.48 | 15.29 | 2.69 | 11.68 | 1.27 | 0.53 | - | ||
| 2021/6 | 0.54 | 27.21 | 7.58 | 2.38 | 11.23 | 1.27 | 0.42 | - | ||
| 2021/5 | 0.42 | 39.42 | 66.63 | 1.84 | 12.35 | 1.31 | 0.41 | 皮下填補劑、關節腔注射劑及可吸收防沾黏業務銷售增加。 | ||
| 2021/4 | 0.3 | -47.25 | 6.49 | 1.42 | 2.36 | 1.11 | 0.48 | - | ||
| 2021/3 | 0.58 | 153.67 | 15.91 | 1.11 | 1.29 | 1.11 | 0.39 | - | ||
| 2021/2 | 0.23 | -26.22 | 13.4 | 0.54 | -10.82 | 1.04 | 0.41 | - | ||
| 2021/1 | 0.31 | -38.91 | -22.96 | 0.31 | -22.96 | 1.12 | 0.38 | - | ||
| 2020/12 | 0.5 | 65.46 | -3.54 | 4.67 | 6.62 | 1.32 | 0.35 | - | ||
| 2020/11 | 0.3 | -40.19 | -21.83 | 4.16 | 8.0 | 1.05 | 0.44 | - | ||
| 2020/10 | 0.51 | 113.76 | 32.44 | 3.86 | 11.36 | 1.45 | 0.32 | - | ||
| 2020/9 | 0.24 | -66.02 | -24.19 | 3.35 | 8.72 | 1.21 | 0.35 | - | ||
| 2020/8 | 0.7 | 160.77 | 118.36 | 3.11 | 12.47 | 1.47 | 0.29 | 皮下填補劑、一針劑型關節腔注射劑及可吸收防沾黏業務銷售增加 | ||
| 2020/7 | 0.27 | -46.33 | -31.34 | 2.41 | -1.45 | 1.03 | 0.41 | - | ||
| 2020/6 | 0.5 | 97.03 | 5.88 | 2.14 | 4.26 | 1.04 | 0.3 | - | ||
| 2020/5 | 0.25 | -10.89 | -16.1 | 1.64 | 3.77 | 1.04 | 0.3 | - | ||
| 2020/4 | 0.29 | -42.58 | 23.64 | 1.38 | 8.5 | 0.98 | 0.32 | - | ||
| 2020/3 | 0.5 | 148.18 | 36.02 | 1.1 | 5.15 | 1.1 | 0.26 | - | ||
| 2020/2 | 0.2 | -49.89 | -11.0 | 0.6 | -11.49 | 1.12 | 0.26 | - | ||
| 2020/1 | 0.4 | -23.51 | -11.74 | 0.4 | -11.74 | 1.31 | 0.22 | - | ||
| 2019/12 | 0.52 | 34.09 | 26.69 | 4.38 | 32.85 | 1.3 | 0.25 | - | ||
| 2019/11 | 0.39 | 1.33 | 13.3 | 3.86 | 33.73 | 1.09 | 0.3 | - | ||
| 2019/10 | 0.38 | 22.35 | 48.51 | 3.47 | 36.51 | 1.02 | 0.32 | - | ||
| 2019/9 | 0.31 | -2.12 | 41.25 | 3.08 | 35.14 | 1.03 | 0.35 | - | ||
| 2019/8 | 0.32 | -18.01 | 44.12 | 2.77 | 34.48 | 1.19 | 0.3 | - | ||
| 2019/7 | 0.39 | -17.23 | 37.17 | 2.44 | 33.31 | 1.17 | 0.31 | - | ||
| 2019/6 | 0.47 | 56.12 | 154.98 | 2.05 | 32.59 | 1.01 | 0.33 | 皮下填補劑、可吸收防沾黏業務銷售增加及IFRS 15合約客戶收入，因原贈針認列遞延收入，實際出庫認列營業收入。 | ||
| 2019/5 | 0.3 | 31.31 | 80.69 | 1.58 | 15.9 | 0.0 | N/A | 皮下填補劑及可吸收防沾黏業務銷售增加 | ||
| 2019/4 | 0.23 | -36.83 | 50.63 | 1.28 | 6.79 | 0.0 | N/A | 皮下填補劑業務銷售增加 |
| 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
|---|---|---|---|---|---|---|---|---|---|
| 2024/1 | 0.74 | 2023/1 | 0.36 | 2022/1 | 0.2 | 2021/1 | 0.31 | 2020/1 | 0.4 |
| 2024/2 | 0.51 | 2023/2 | 0.24 | 2022/2 | 0.23 | 2021/2 | 0.23 | 2020/2 | 0.2 |
| 2024/3 | 0.71 | 2023/3 | 0.6 | 2022/3 | 0.57 | 2021/3 | 0.58 | 2020/3 | 0.5 |
| N/A | N/A | 2023/4 | 0.5 | 2022/4 | 0.32 | 2021/4 | 0.3 | 2020/4 | 0.29 |
| N/A | N/A | 2023/5 | 0.62 | 2022/5 | 0.44 | 2021/5 | 0.42 | 2020/5 | 0.25 |
| N/A | N/A | 2023/6 | 0.71 | 2022/6 | 0.57 | 2021/6 | 0.54 | 2020/6 | 0.5 |
| N/A | N/A | 2023/7 | 0.69 | 2022/7 | 0.59 | 2021/7 | 0.31 | 2020/7 | 0.27 |
| N/A | N/A | 2023/8 | 0.81 | 2022/8 | 0.39 | 2021/8 | 0.55 | 2020/8 | 0.7 |
| N/A | N/A | 2023/9 | 0.57 | 2022/9 | 0.68 | 2021/9 | 0.41 | 2020/9 | 0.24 |
| N/A | N/A | 2023/10 | 0.6 | 2022/10 | 0.51 | 2021/10 | 0.34 | 2020/10 | 0.51 |
| N/A | N/A | 2023/11 | 0.62 | 2022/11 | 0.44 | 2021/11 | 0.38 | 2020/11 | 0.3 |
| N/A | N/A | 2023/12 | 0.81 | 2022/12 | 0.65 | 2021/12 | 0.68 | 2020/12 | 0.5 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
| 23Q4 (20) | 0.07 | 133.33 | 600.0 |
| 23Q3 (19) | 0.03 | 200.0 | -57.14 |
| 23Q2 (18) | 0.01 | -50.0 | -85.71 |
| 23Q1 (17) | 0.02 | 100.0 | 0 |
| 22Q4 (16) | 0.01 | -85.71 | -50.0 |
| 22Q3 (15) | 0.07 | 0.0 | -36.36 |
| 22Q2 (14) | 0.07 | 0 | -36.36 |
